Padegimas
Linas Padegimas, Mayfield Heights, OH US
Patent application number | Description | Published |
---|---|---|
20100203627 | LONG-TERM IN VIVO TRANSGENE EXPRESSION - Efficient and prolonged hCFTR expression is one of the major obstacles for cystic fibrosis lung therapy. hCFTR mRNA expression levels depend on eukaryotic expression cassette components, prokaryotic backbone elements, and the gene transfer method may also influence transcriptional silencing mechanisms. A codon-optimized and CpG-reduced human CFTR gene (CO-CFTR) was made. Various vector modifications were tested to facilitate extended duration of CO-CFTR expression. Insertion of an extended 3′BGH transcribed sequence (712 bp) in an inverted orientation produced prolonged expression of CO-CFTR expression at biologically relevant levels. Further studies revealed that prolonged CO-CFTR expression is dependant on the orientation of the extended BGH 3′ BGH transcribed sequence and its transcription, is not specific to the UbC promoter, and is less dependent on other vector backbone elements. | 08-12-2010 |
20110035819 | CODON OPTIMIZED CFTR - A synthetic hCFTR DNA sequence has been developed that produces remarkably high levels of hCFTR mRNA and protein in dosed murine lungs and human cells in culture compared to the natural hCFTR cDNA. This synthetic DNA addresses problems inherent in some natural cDNAs, such as premature transcriptional truncation sites introduced during cDNA synthesis. Introns are initially present in mRNA until the mRNA is processed. cDNA made from processed mRNA is devoid of introns. Thus DNA sequences (exon junctions) are present in a cDNA molecule which are not present in cells in nature. These exon junctions may affect transcription. Methods for improving expression of CFTR are based on sequence changes in cDNA molecules. The improvement methods may be applied to other cDNA molecules which are refractory to in vivo expression efforts. Compositions embodying the sequence changes increase the production of both transgenic mRNA and protein from cDNA molecules. | 02-10-2011 |
Stanley Padegimas, Mobile, AL US
Patent application number | Description | Published |
---|---|---|
20100240810 | Liquid Oxyalkylene Bridged Bis- andTris-Phosphite Ester Mixtures - Disclosed are mixtures of oxyalkylene bridged bis- and tris-phosphite esters of formulae I and II | 09-23-2010 |
Stanley J. Padegimas, Mobile, AL US
Patent application number | Description | Published |
---|---|---|
20100029844 | Liquid polymeric phosphites and phosphonites as stabilizers - Novel liquid polymeric compounds of the formula (I) wherein the general symbols are as defined in claim | 02-04-2010 |